Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL

Clinical trial NCT00274742 · COMPLETED

Trial details

NCT number: NCT00274742
Sponsor: Amgen Research (Munich) GmbH
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Non-Hodgkin's Lymphoma, Relapsed

Start date: 2004-06-01
Primary completion: 2011-08-01
Enrollment: 76

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.